Company profile
Adial Pharmaceuticals, Inc.
NASDAQ: ADIL · Healthcare · Biotechnology
PublicHQ Charlottesville, VACIK 0001513525Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 36DQ —GM —SS 32
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, market scale · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$8.0M
Employees
5
as of 2026-09-22
Market cap
$4.2M
as of 2026-09-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$8.0M-$8.0M2025
Operating income-$7.8M-$7.8M2025
Total assets$6.7M$6.7M2025
Liabilities$1.4M$1.4M2025
Equity$5.3M$5.3M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Adial Pharmaceuticals, Inc.’s financial profile?
Adial Pharmaceuticals, Inc. earned -$8.0M in FY2025 net income.
Peers · Healthcare
Lakewood-Amedex Biotherapeutics Inc. Common Stock——CordovaCann Corp.——KMA Holding, Inc.——Cadrenal Therapeutics, Inc. Common Stock——Revelation Biosciences, Inc.——Medicus Pharma Ltd. Common Stock——Key facts
CEOCary John Claiborne
SectorHealthcare
IndustryBiotechnology
HeadquartersCharlottesville, VA
ExchangeNASDAQ: ADIL
Employees5
IPO date2018-07-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.